Pharming Group (NASDAQ:PHAR) Sees Unusually-High Trading Volume

Shares of Pharming Group (NASDAQ:PHAR - Get Free Report) saw unusually-high trading volume on Wednesday . Approximately 10,737 shares were traded during mid-day trading, an increase of 148% from the previous session's volume of 4,336 shares.The stock last traded at $8.18 and had previously closed at $7.82.Get Pharming Group alerts:Wall Street Analyst Weigh InSeparately, HC Wainwright reiterated a "buy" rating and issued a $37.00 target price on shares of Pharming Group in a research report on Thursday, August 1st.Check Out Our Latest Research Report on Pharming GroupPharming Group Stock Up 4.6 %The firm has a market cap of $550.87 million, a P/E ratio of -48.88 and a beta of 0.15. The company has a current ratio of 3.39, a quick ratio of 2.65 and a debt-to-equity ratio of 0.40. The company's 50 day simple moving average is $8.14 and its 200-day simple moving average is $9.60. Pharming Group (NASDAQ:PHAR - Get Free Report) last released its earnings results on Thursday, August 1st. The company reported ($0.01) EPS for the quarter. Pharming Group had a negative return on equity of 5.69% and a negative net margin of 4.65%. The company had revenue of $74.09 million during the quarter, compared to analysts' expectations of $71.95 million. During the same period last year, the firm posted $0.02 EPS. Research analysts forecast that Pharming Group will post -0.03 earnings per share for the current fiscal year. Institutional Inflows and OutflowsA hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its holdings in shares of Pharming Group (NASDAQ:PHAR - Free Report) by 32.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,435 shares of the company's stock after acquiring an additional 5,725 shares during the period. Silverberg Bernstein Capital Management LLC's holdings in Pharming Group were worth $196,000 at the end of the most recent reporting period. 0.03% of the stock is currently owned by institutional investors and hedge funds. Pharming Group Company Profile (Get Free Report)Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.Featured ArticlesFive stocks we like better than Pharming Group3 Healthcare Dividend Stocks to BuyTarget Hits the Mark: Q2 Earnings Exceed ExpectationsHow to Start Investing in Real EstateIs Tesla’s Rebound Just Starting? Why You Should Consider BuyingWhat Investors Must Know About Over-the-Counter (OTC) StocksStanley Druckenmiller's Latest Bet: MELI—Should You Follow Suit?This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.→ Elites' Plot: Control Trump and YOUR Money! (From Golden Crest) (Ad)Should you invest $1,000 in Pharming Group right now?Before you consider Pharming Group, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.While Pharming Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here